GU Cancers 2020 | CaboPoint: second-line cabozantinib for RCC
Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CaboPoint trial (NCT03945773). This study focuses on cabozantinib as a second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up